Entera Bio Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ENTX Nasdaq 8731 https://enterabio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Entera Bio Ltd

OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations - Sep 13th, 2023 5:18 pm
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes - Sep 12th, 2023 12:30 pm
Entera Bio to Participate in Upcoming Investor Conferences - Sep 5th, 2023 12:00 pm
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth? - Aug 24th, 2023 10:25 am
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting - Aug 16th, 2023 12:30 pm
Entera Bio Announces Q2 2023 Financial Results and Corporate Updates - Aug 11th, 2023 8:05 pm
Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors - Jun 7th, 2023 11:30 am
Entera Bio First Quarter 2023 Earnings: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022) - May 7th, 2023 12:10 pm
Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates - May 5th, 2023 9:15 pm
Entera Bio Announces Q1 2023 Financial Results and Corporate Updates - May 5th, 2023 8:05 pm
Will Entera Bio Ltd. (ENTX) Report Negative Q1 Earnings? What You Should Know - May 4th, 2023 2:00 pm
Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics - May 3rd, 2023 1:34 pm
Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board - Apr 26th, 2023 12:30 pm
Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program - Apr 3rd, 2023 11:00 am
Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates - Mar 31st, 2023 9:15 pm
Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022 - Mar 31st, 2023 8:00 pm
Entera Bio Regains Compliance with Nasdaq Listing Requirements - Mar 23rd, 2023 1:27 pm
Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely? - Mar 10th, 2023 1:05 pm
Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards? - Feb 20th, 2023 1:34 pm
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis - Feb 15th, 2023 3:00 pm